Vandetanib (Caprelsa) for the indication ‘metastatic medullary thyroid cancer’

Vandetanib has a therapeutic added value in comparison with placebo for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease, provided that treatment is limited to
patients in whom the disease follows a symptomatic and aggressive course.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.